Ionis to present at TD Cowen Genetic Medicines & RNA Summit
Ionis Pharmaceuticals announced that its management will participate in a fireside chat at the TD Cowen Genetic Medicines & RNA Summit on June 20, 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ionis Pharmaceuticals announced that its management will participate in a fireside chat at the TD Cowen Genetic Medicines & RNA Summit on June 20, 2024. The event will be virtual, and a live webcast will be available on the Ionis website. Interested parties can access the webcast on the Investors & Media section of the website, with a replay available within 48 hours for a time.
Positive
- Ionis Pharmaceuticals' participation in the TD Cowen Genetic Medicines & RNA Summit increases visibility in the industry.
- Hosting a virtual fireside chat allows broader access to potential investors and stakeholders.
- Availability of a live webcast and replay enhances transparency and investor engagement.
Negative
- replay availability may restrict access for those unable to attend the live event.
Details
News Market Reaction – IONS
The recorded move for IONS in the trading session of this news was -0.29%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live webcast of this presentation can be accessed on the Investors & Media section of the Ionis website at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available on the Ionis website within 48 hours and will be archived for a limited time.
About Ionis Pharmaceuticals
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients.
To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) and LinkedIn.
Ionis Pharmaceuticals Investor Contact:
D. Wade Walke, Ph.D. – ir@ionis.com – 760-603-2331
Ionis Pharmaceuticals Media Contact:
Hayley Soffer – media@ionis.com – 760-603-4679
View original content to download multimedia:https://www.prnewswire.com/news-releases/ionis-to-present-at-td-cowen-genetic-medicines--rna-summit-302174669.html
SOURCE Ionis Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.